Construction and characterization of a live, attenuated apxIICA inactivation mutant of Actinobacillus pleuropneumoniae lacking a drug resistance marker
Construction and characterization of a live, attenuated apxIICA inactivation mutant of Actinobacillus pleuropneumoniae lacking a drug resistance marker
复制标题
DOI：
10.1016/j.femsle.2004.11.033
复制
发表时间：
2005-02-01
影响因子：
2.1
通讯作者：
Chen, HC
中科院分区：
文献类型：
--
作者：
Bei, WC;He, QG;Chen, HC
通过蔗糖反向选择标记系统的同源重组，使7型胸膜肺炎放线杆菌的apxIIC基因失活，得到一株没有抗生素抗性标记的突变株，该突变株表达灭活的ApxII毒素。对突变体的安全性和免疫原性进行了评价。突变株经腹腔给药剂量达2×10(9)cfu时对小鼠无不良反应，而亲本株在2×107cfu剂量下可致小鼠死亡。对胸膜肺炎沙门氏菌同源(血清7型)和异源(血清I3型)攻击的保护率分别为100%和70%。研究中使用的胸膜肺炎弧菌突变株HB04C(-)和反选择方法在开发猪胸膜肺炎和其他呼吸系统感染性疾病的有效活疫苗方面具有前景。(C)2004年欧洲微生物学会联合会。爱思唯尔出版，版权所有。
The apxIIC gene of Actinobacillus pleuropneumoniae serotype 7 was inactivated by homologous recombination using a sucrose counter-selectable marker system, resulting in a mutant strain that had no antibiotic resistance marker and expressed an inactivated ApxII toxin. The safety and immunogenicity of the mutant were evaluated in mice. The mutant strain caused no adverse effects in mice at doses up to 2 x 10(9) CFU via the intraperitoneal route while the parental strain induced total mortality at a dose of 2 x 107 CFU. Mice vaccinated intraperitoneally with the mutant strain had 100% and 70%, protection against homologous (serotype 7) or heterologous (serotype I 3) challenge with A. pleuropneumoniae, respectively. The A. pleuropneumoniae mutant strain HB04C(-) and the counterselection method used in the study show promise in developing effective live vaccines for porcine pleuropneumonia and for other infections diseases of the respiratory system. (C) 2004 Federation of European Microbiological Societies. Published by Elsevier B.V. All rights reserved.